News

Hims’ second-quarter revenue fell 7% from a quarter ago. The decline goes beyond weakness in its GLP-1 weight-loss business.
Technological innovation and personalized care are transforming Hims & Hers into a proactive health platform. Read why I ...
Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. Click here to find out why ...
Shares of Hims & Hers fell nearly 9% on Tuesday after the telehealth firm reported weaker-than-expected quarterly revenue, in part as its move from branded to lower-cost, personalized weight loss ...
On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...
Hims & Hers is a top telehealth stock with strong revenue growth, innovative offerings, and long-term potential. Click here ...
Shares of telehealth firm Hims & Hers fell as much as 5% on Tuesday after the company reported weaker-than-expected second-quarter revenue, hurt by a loss of subscribers in its weight-loss treatment ...